- Home
- XFOR vs EPIX Comparison
XFOR vs EPIX Comparison
Compare XFOR & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- EPIX
- Stock Information
- Founded
- XFOR 2014
- EPIX 2009
- Country
- XFOR United States
- EPIX Canada
- Employees
- XFOR N/A
- EPIX N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- EPIX Health Care
- Exchange
- XFOR Nasdaq
- EPIX Nasdaq
- Market Cap
- XFOR 84.3M
- EPIX 75.9M
- IPO Year
- XFOR N/A
- EPIX N/A
- Fundamental
- Price
- XFOR $3.64
- EPIX $0.23
- Analyst Decision
- XFOR Strong Buy
- EPIX Hold
- Analyst Count
- XFOR 3
- EPIX 3
- Target Price
- XFOR $34.17
- EPIX $2.00
- AVG Volume (30 Days)
- XFOR 10.6M
- EPIX 14.4M
- Earning Date
- XFOR 08-08-2025
- EPIX 08-13-2025
- Dividend Yield
- XFOR N/A
- EPIX N/A
- EPS Growth
- XFOR N/A
- EPIX N/A
- EPS
- XFOR N/A
- EPIX N/A
- Revenue
- XFOR $32,774,000.00
- EPIX N/A
- Revenue This Year
- XFOR $1,313.84
- EPIX N/A
- Revenue Next Year
- XFOR N/A
- EPIX N/A
- P/E Ratio
- XFOR N/A
- EPIX N/A
- Revenue Growth
- XFOR 5721.31
- EPIX N/A
- 52 Week Low
- XFOR $1.35
- EPIX $0.22
- 52 Week High
- XFOR $26.83
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- XFOR 51.62
- EPIX 5.58
- Support Level
- XFOR $3.57
- EPIX $0.22
- Resistance Level
- XFOR $4.83
- EPIX $0.26
- Average True Range (ATR)
- XFOR 0.55
- EPIX 0.02
- MACD
- XFOR -0.05
- EPIX -0.15
- Stochastic Oscillator
- XFOR 26.94
- EPIX 0.62
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.